VETERINARY TEAM REFERENCE

DEA & state schedules

Scheduling applies to the medication, not to the patient. This independent reference is not affiliated with the DEA.

Fluconazole

FEDERAL STATUS

Not federally scheduled

The identified ingredients in this entry are not listed in the reviewed federal schedules. Prescription-only status, product restrictions and state law are separate questions.

Federal source ↗

State / prescribing or dispensing jurisdiction

STATE STATUS

Select a jurisdiction

Choose the state relevant to prescribing or dispensing. Patient residence alone may not determine every applicable rule.

What each federal schedule means

Highlighted rows match the verified federal or selected state schedule. The schedule describes legal control and abuse potential; it does not rank clinical usefulness or establish a dose.

Federal Schedules I–V: meaning and practice implications
Schedule	Meaning and practice
I	High abuse potential; no currently accepted medical use in U.S. treatment; lacks accepted safety under medical supervision. In practice: Not available for routine veterinary prescribing. Authorized research is a separate pathway.
II	High abuse potential; accepted medical use, sometimes with severe restrictions; abuse can cause severe dependence. In practice: No prescription refills under federal law. Strict prescribing, security and record requirements apply.
III	Less abuse potential than I or II; accepted medical use; abuse can cause moderate or low physical dependence or high psychological dependence. In practice: Federal prescriptions allow up to five authorized refills within six months. State rules may be stricter.
IV	Lower abuse potential than III; accepted medical use; limited dependence risk relative to III. In practice: The same federal five-refill / six-month prescription limit applies. Controlled-drug handling still applies.
V	Lower abuse potential than IV; accepted medical use; limited dependence risk relative to IV. In practice: Still controlled. Check authorized refills and state limits; do not automatically apply the III–IV refill rule.

What this means for the chart

For a controlled medication, confirm the prescriber’s authority for the applicable schedule, the exact formulation and quantity, authorized refills, secure handling, and required inventory / dispensing records. Check the state’s veterinary rules and any prescription monitoring program (PDMP) requirements or exemptions.

A PDMP reporting requirement does not by itself make a drug scheduled. “Not federally scheduled” does not mean over the counter, risk-free, or exempt from state law. States may use additional categories, such as Schedule VI, outside the federal I–V system.

← Medication & Supplement Reference

VETERINARY TEAM REFERENCE · MEDICATION

Fluconazole

A triazole antifungal. Selecting it requires identifying the likely organism and infection site; a fungal diagnosis does not make all azole medications equivalent.

Triazole antifungalProduct-specific clinical reference

Updated October 16, 2026 · Sources and review status below

For veterinarians and veterinary staff. Product-label information is distinct from extra-label clinical practice. This is not a complete prescribing formulary or an automated interaction screen. Verify the current label, exact formulation, patient and species-specific clinical reference before use. Independent veterinary/pharmacy review remains pending.

Prescribing overview

Diflucan is a human oral antifungal. Organism susceptibility and infection site matter: some non-albicans Candida species are inherently resistant. Its human indications and renal adjustments do not establish an animal regimen.

Key prescribing checks

Review renal function because the human label describes predominantly renal elimination and adjustments for impaired renal function. Do not transfer human adjustment thresholds into veterinary prescribing.
Review hepatic history and plan surveillance for suspected liver injury. Adverse signs require clinical assessment rather than automatic continuation until a planned course ends.
Check drug interactions, especially combinations that prolong QT or are affected by azole enzyme inhibition. This overview is not an exhaustive interaction screen.

Uses by species

Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.

Humans (reference label)

Human-approved; veterinary regimen not established by this source

Specified Candida infections and cryptococcal meningitis

Animal prescribing requires a separate veterinary assessment.

Use / indication source ↗

Pharmacology & pharmacokinetics

Mechanism and clinical role

Inhibits fungal lanosterol demethylation and ergosterol synthesis; inhibits CYP2C19, CYP2C9 and CYP3A4.

Absorption, distribution, metabolism and elimination

Human volunteers: oral bioavailability exceeds 90%, terminal half-life approximately 30 hours; predominantly renal elimination. These are not canine/feline PK values.

SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC

Contraindications & cautions

Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.

Diflucan

U.S. human oral tablets and suspension label; not veterinary approval.

Contraindications · when not to use

Hypersensitivity to fluconazole or excipients.
Concomitant CYP3A4-metabolized QT-prolonging medicines, including erythromycin, pimozide and quinidine.

Precautions & monitoring

Liver dysfunction, renal impairment, arrhythmia risks and pregnancy require review. Suspension contains sucrose and has additional inherited sugar-metabolism restrictions.

Safety sources checked: October 16, 2026. Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.

Adverse effects

Human labeling reports gastrointestinal effects, serious hepatic injury, severe skin reactions and QT-related arrhythmias.

These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.

Dosing & administration

Verify the source before prescribing. The regimens below summarize selected veterinary product labels, not every accepted veterinary use. They are not automatic substitutions between brands or formulations. Renal/hepatic disease, concurrent therapy, age, indication and clinical response can require a different plan.

A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.

No approved veterinary dose verified in the reviewed human label; no human-to-animal dose conversion supplied.

Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗

Drug & supplement interactions

This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.

Diflucan

U.S. human oral tablets and suspension label; not veterinary approval.

CYP2C9/2C19/3A4 inhibition creates many interactions; review the complete label.

Interaction source ↗

Monitoring

Review kidney/liver function and the complete interaction list; assess QT-prolonging combinations.

Client counseling

Confirm suspension concentration; report suspected intolerance to the prescriber.

This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.

Storage & handling

Reconstituted suspension requires its product-specific storage and discard instructions.

Brands, formulations & ingredient identity

Active ingredients

fluconazole

Diflucan maps to fluconazole, not itraconazole or terbinafine. Brand recognition helps reconciliation but does not determine the best antifungal for a particular patient.

The cited U.S. oral label includes tablets and powder reconstituted as suspension. Record the actual dosage form and liquid concentration rather than relying on the brand alone.

This is human labeling. Animal use and any compounded preparation require veterinary direction and a separate product check.

Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.

Diflucan

Formulation: Oral tablets and powder for suspension
Label / product scope: Human product

Human-approved antifungal; veterinary use is not established by this label.

Product label / source ↗

References & review status

Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.

01DailyMed: Diflucan prescribing information ↗

Search another medication or supplement →

Prescribing overview

Key prescribing checks

Uses by species

Humans (reference label)

Pharmacology & pharmacokinetics

Mechanism and clinical role

Absorption, distribution, metabolism and elimination

Contraindications & cautions

Contraindications · when not to use

Precautions & monitoring

Adverse effects

Dosing & administration

Drug & supplement interactions

Diflucan

Monitoring

Client counseling

Storage & handling

Brands, formulations & ingredient identity

Active ingredients

Diflucan

References & review status

Related Resources